Figure 2.

Flow chart to select combinatorial therapies stratified by expression of EMT markers. KRAS mutant lung cancer is determined whether tumor cells have epithelial or mesenchymal phenotype according to the expression of representative EMT markers, E-cadherin, vimentin, ERBB3, and FGFR1. When ERBB3 and E-cadherin are positive, the patients are treated with combination of MEK inhibitor and ERBB3 inhibitor. On the other hand, when FGFR1 and vimentin are positive, combination of the MEK inhibitor with FGFR1 inhibitors is chosen. Because not all tumors can be defined either subtype, more markers or other treatment strategies against mixed phenotype are needed to be identified. IHC; immunohistochemistry.